On the other hand, in advanced NSCLC, PD-L1 expression levels were higher in BRAF (p = 0.009), KRAS (p = 0.0001), MET (p = 0.02) mutated tumors and in tumors harboring gene fusions (p = 0.03) in comparison to wild-type tumors. This evidence concerns the gene MET and non-small cell lung carcinoma.